SCHEMBL17617

SCHEMBL17617

C[C@](O)(c1ccc(N2CCN(S(=O)(=O)c3cccs3)C[C@@H]2Cc2ccncc2)cc1)C(F)(F)F

nearest known ligand 0.85

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 13/20 0.85
GCK P35557 7/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17561 1.00 GCKR (0.85) GCKRGCK
SCHEMBL16768 1.00 GCKR (0.85) GCKRGCK
Trifluoroacetic Acid SCHEMBL12078254 0.96 GCKR (0.79) GCKRGCK
Trifluoroacetic Acid SCHEMBL12078953 0.96 GCKR (0.79) GCKRGCK
Trifluoroacetic Acid SCHEMBL12078468 0.96 GCKR (0.79) GCKRGCK
Trifluoroacetic Acid SCHEMBL16763 0.96 GCKR (0.79) GCKRGCK
Trifluoroacetic Acid SCHEMBL12079101 0.96 GCKR (0.79) GCKRGCK
Trifluoroacetic Acid SCHEMBL16889 0.96 GCKR (0.79) GCKRGCK
Trifluoroacetic Acid SCHEMBL17038 0.96 GCKR (0.79) GCKRGCK
SCHEMBL16547 0.93 GCKR (0.85) GCKRGCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 GCKR 1/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.